| Literature DB >> 32689795 |
Brianna D Mackie1, Dongxing Chen2, Guangping Dong2, Cheng Dong3, Haley Parker4, Christine E Schaner Tooley4, Nicholas Noinaj5, Jinrong Min3, Rong Huang1,2.
Abstract
Protein N-terminal methyltransferases (NTMTs) methylate the α-N-terminal amines of proteins starting with the canonical X-P-K/R motif. Genetic studies imply that NTMT1 regulates cell mitosis and DNA damage repair. Herein, we report the rational design and development of the first potent peptidomimetic inhibitor for NTMT1/2. Biochemical and cocrystallization studies manifest that BM30 (with a half-maximal inhibitory concentration of 0.89 ± 0.10 μM) is a competitive inhibitor to the peptide substrate and noncompetitive to the cofactor S-adenosylmethionine. BM30 exhibits over 100-fold selectivity to NTMT1/2 among a panel of 41 MTs, indicating its potential to achieve high selectivity when targeting the peptide substrate binding site of NTMT1/2. Its cell-permeable analogue DC432 (IC50 of 54 ± 4 nM) decreases the N-terminal methylation level of the regulator of chromosome condensation 1 and SET proteins in HCT116 cells. This proof-of principle study provides valuable probes for NTMT1/2 and highlights the opportunity to develop more cell-potent inhibitors to elucidate the function of NTMTs in the future.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32689795 PMCID: PMC7486280 DOI: 10.1021/acs.jmedchem.0c00689
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446